Disease development is often shaped by genetics, with how much or how little a gene is expressed influencing disease risk.
Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback